We started Mercaptor because science moves forward on unsteady feet relying on a tiny amount of fortuity mixed into a vast trough of human frailty.
Captons are unlike any drugs found in the historical pharmacopeia. They are enhanced by design, with chemosensitivity matched to conditions within distressed tissue. The ability to deliver a measured, countervailing response upon encountering pathology, but not before, directly addresses problems which have historically thwarted efforts to develop pharmacological interventions that yield meaningful benefit. Captons are engaged by specific metabolites elevated within damaged or diseased brain tissue. The primary response is the conversion of captons, in situ, from silent to active therapeutics. Conversion occurs rapidly and efficiently, driven by multiple neuropathological sources of oxidative stress. Capton activation, therefore, is localized to those areas of the CNS that would benefit from active capton. Duration of tissue exposure to activated capton is also partly determined by those intervals during which pathophysiology defines cellular behavior.
Mercaptor has directed its drug-development efforts toward epilepsy and traumatic brain injury, which share key features of pathophysiology relevant to COVID19. By expanding our approach in the lab, we have been able to begin resourcing programs to ease the suffering caused by the pandemic. Each of the three drug candidates selected for accelerated development at Mercaptor brings documented anti-inflammatory potency acting on separate, but complementary, pathways.
Avoiding the false comfort of certainty, honest scientists sometimes catch a glimpse into the infinite Universe.
These rare insights are more likely to help move the world forward than countless years spent trying to prove expectations. The opportunity obliges us to take responsibility for the continued development of what we have learned.
https://www.prnewswire.com/news-releases/mercaptor-discoveries-advances-drug-candidate-to-treat-brain-inflammation-in-people-with-long-covid-301318107.html Mercaptor Discoveries (Mercaptor) today advanced their therapeutic candidate to treat brain-inflammation found in patients with long COVID, also known as post-acute sequelae of COVID-19. Long
Mercaptor Discoveries Uses its Proprietary Neurotherapeutic Platform to Develop Treatment for COVID-19
NOVATO, Calif., May 18, 2020 /PRNewswire/ — Mercaptor Discoveries (Mercaptor), a platform company with preclinical programs in epilepsy and TBI, today announced that it is pivoting its
I am so proud of the Mercaptor team, talented scientists and researchers who have shown their dedication to health once again during a time of
The purpose of Concussion Mom is to educate and raise awareness about concussions. Concussion Mom began as a way to coach and educate concussion survivors
On February 25, 2020, the Mercaptor Discoveries team participated in the 5th Annual Rare Disease Day Virtual Race by walking a 5K. The walk was
Mercaptor Discoveries is developing drugs and therapies that we hope can be a major tool in the battle against Traumatic Brain Injury (TBI). While most
Can Mercaptor Discoveries research save the game of football? These questions and more are addressed in this recent article from our friends at SB Nation.
NOVATO, Calif., Jan. 9, 2020 /PRNewswire/ — Mercaptor Discoveries (Mercaptor), a company developing therapeutic agents active exclusively at the site of injury, announced the advancement of its